New antibody takes aim at Hard-to-Treat cancers
Disease control
Recruiting now
This early-phase trial is testing a new drug called IUAb190708, an antibody designed to attack cancer cells by targeting a protein called PD-L1. The study involves 90 adults with advanced or recurrent solid tumors who have run out of standard treatment options. The main goal is t…
Phase: PHASE1 • Sponsor: Jun Zhou • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC